




TROG 2024
12 - 15 March 2024
Newcastle NSW
Together Towards Tomorrow


TROG SCIENTIFIC COMMITTEE

A/Prof Sasha Senthil, Alfred Health

 @TROGfightcancer
#TROGCancerResearch
#TROG2024

2023 Highlights

TROG Concept Development Workshop, 31 May 2023



2023 Highlights

- 6 new trial proposals submitted (4 Cat A | 1 Cat B)
- 4 trial proposal accepted for development
 - Cat A; TD 23.01 REMASTER, TD 23.02 & TD 23.03 2SHOTS | Cat B; TD 23.04 PEARLS
- Continuing trial activity with 29 open trials and 12 trials in development.
- 230 participants recruited, bringing overall accrual on TROG trials to 15,350.
- TROG 12.01 HPV OROPHARYNX achieved completion of follow up for all participants
Trial Chairs: Prof Danny Rischin, Peter MacCallum Cancer Centre VIC and Prof June Corry, St Vincent's Hospital VIC
- Results of TROG 15.03 FASTRACK II, TROG 17.02 OUTRUN and TROG 13.01 SAFRON II presented at major international meeting.
- Ten manuscripts published relating to TROG studies.

2024 Highlights... so far

- 2 trial proposals accepted for development
 - Cat A; TD 24.01 MODERN-LUNG | Cat B; TD 24.02
- 38 participants recruited so far
 - TROG 18.01 NINJA has recruited its 300th Participant
Congratulations to Prof Andrew Miller and the team from Illawarra Cancer Care Centre on recruiting this participant.
 - TROG 20.01 CHEST RT have met recruitment milestones early and on track to finishing the recruitment period early.
- TROG's first teletrial site was activated in February.
 - Royal Darwin Hospital is now recruiting to TROG 21.07 SOCRATES HCC (teletrial site to Flinders Medical Centre).

- TROG 16.02 Local HER-O results published in Breast

Phillips C, Pinkham MB, Moore A, Sia J, Jeffree RL, Khasraw M, Kam A, Bressel M, Haworth A. Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02). Breast. 2024 Feb 5;74:103675. doi: 10.1016/j.breast.2024.103675. Epub ahead of print. PMID: 38340685.

- TROG 15.03 FASTRACK II results published in Lancet Oncology

Siva S, Bressel M, Sidhom M, Sridaran S, Vanneste B, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Rama A, Hardcastle N, Hofman M, DeAbreu Lourenco R, Shaw M, Mancuso P, Moon D, Wog L, Lawrentschuk N, Wood S, Brook N, Kron T, Martin J, Pryor D (2024) Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. The Lancet. 2024 Mar; 25(3):308-316. DOI:https://doi.org/10.1016/S1470-2045(24)00020-2

What's in the pipeline?

TRACKING	STUDY ACRONYM	STUDY TITLE	PROPONENT	CAT	STATUS
22F	TAILOR-BEV	Tailored Bevacizumab dose for symptomatic radiation necrosis after stereotactic radiosurgery for brain metastases	Kylie Jung	A	New Proposal
24.02		NRGHN014, Randomized Phase III Trial of Immunotherapy with Response-Adapted treatment versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma	Danny Rischin	B	Development
24.01	MODERN-LUNG	Moderately hypofractionated chemoradiation followed by immunotherapy for inoperable Stage 3 Non-Small Cell Lung Cancer given with radical intent in older adults (MODERN-LUNG): a randomised trial	Jane Ludbrook	A	Development
23.04	PEARLS	A phase II/III trial of Primary radiotherapy for Androgen sensitive prostate cancer patients with Lymph nodeS	Niluja Thiru	B	Development
23.03	2SHOTS	2-fraction Stereotactic radiotherapy Of The prostate	Wee Loon Ong	A	Development
23.02		Multi-fraction preoperative radiosurgery (Pre-SRS) for patients with brain metastases requiring surgery.	Neda Haghighi	A	Development
23.01	REMASTER	Reduced Margin Stereotactic body radiotherapy for prostate cancer: A phase III randomised trial	Muhammad Ali	A	Development
22.02	BETTER	Bevacizumab and immune checkpoint inhibitors plus hypofractionated stereotactic radiotherapy for the treatment of symptomatic melanoma brain metastases	Tim Wang	C	Development
22.01	RT Prepare Mask	RT Prepare Mask: development and testing of a psycho education intervention for people requiring immobilisation masks during radiotherapy	Georgia Halkett	C	Development
21.13	NEEDS	Neoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed	Trevor Leong	C	Development
21.11	ASCENDE-SBRT	Androgen suppression combined with elective nodal and dose escalation with stereotactic body radiation therapy or brachytherapy	Wee Loon Ong	B	Development
21.10	PRIME_LUNG	A randomised phase 2 trial of up-front stereotactic radiotherapy before standard-of-care systemic therapy in advanced lung cancer	Shankar Siva	C	Development
21.09	OCTAVO	A phase II study of consolidation radiation for induced oligo-persistent disease following initial immunotherapy	Eric Hau	C	Development
21.08	VITaL	The Ventilation Imaging for Thoracic Lung cancer radiation therapy trial	Paul Keall	A	Development
18.07	ACCELERATE	TROG ACCELERATE Project: ACCELERating cancer therapy research via a national collated data set	TROG PT SIG	A	Development
21.06	MRL SABR	MRI-Guided Stereotactic Ablative Radiotherapy for Abdominal Malignancies	Trang Pham	C	Start-up

CURRENT TRIALS


TROG No.	STUDY ACRONYM	STUDY TITLE	Chair (TROG RO lead for Cat B&C)	CAT	STATUS
21.12	ASPIRE	Australian Proton Therapy Clinical Quality Registry (APTCQR)	Hien Le	A	Open (Recruiting)
21.07	SOCRATES HCC	A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC	David Pryor & Alan Wigg	A	Open (Recruiting)
20.01	CHEST RT	A phase II study of carboplatin and etoposide chemotherapy, durvalumab with or without thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer	Eric Hau & Sagun Parakh	A	Open (Recruiting)
19.06	DECREASE	Darolutamide + Consolidation RadiothErapy in Advanced proStatE cancer detected by PSMA	Shankar Siva & Arun Azad	A	Open (Recruiting)
18.06	FIG	Prospective, multicentre trial evaluating FET-PET in Glioblastoma	Eng-Siew Koh & Andrew Scott	A	Open (Recruiting)
18.01	NINJA	Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation	Jarad Martin & Mark Sidhom	A	Open (Recruiting)
21.04	ADELE	ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk Endometrial cancer (ADELE): a randomised phase 2 trial	Yeh Chen Lee (Pearly Khaw)	C	Open (Recruiting)
21.03	RESOLUTE	Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer	Jeanne Tie & (Julie Chu)	C	Open (Recruiting)
21.02	Dasl-HiCaP	Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.	Christopher Sweeney & Tamim Niazi	C	Open (Recruiting)
21.01	I-MAT	Immunotherapy Merkel Adjuvant Trial	Wen Xu / (Michael Poulsen)	C	Open (Recruiting)
18.04	MASTERPLAN	Randomised phase II study from the AGITG Mfolirinox And STereotactic Radiotherapy for Pancreatic cancer with Locally AdvaNced disease	Andrew Oar	C	Open (Recruiting)
17.11	CPOST	A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma	Danny Rischin & Sandro Porceddu	C	Open (Recruiting)
16.04	EXPERT	A randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised low-risk luminal A early breast cancer (EXPERT)	Boon Chua	C	Open (Recruiting)

CURRENT TRIALS


TROG No.	STUDY ACRONYM	STUDY TITLE	Chair (TROG RO lead for Cat B&C)	CAT	STATUS
17.03	LARK	Liver Ablative Radiotherapy utilising Kilovoltage intrafraction monitoring (KIM)	Dominique Lee & Tim Wang	A	Open (Follow up)
17.02	OUTRUN	Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases	Yu Yang Soon, Chee Lee & Fiona Hegi-Johnson	A	Open (Follow up)
15.03	FASTRACK II	Focal Ablative STereotactic RADiosurgery for Cancers of the Kidney - a Phase II Clinical Trial	Shankar Siva	A	Open (Follow up)
12.02	PET LABRADOR	PET scans for locally advanced breast cancer and diagnostic MRI to determine the extent of operation and radiotherapy	Verity Ahern	A	Open (Follow up)
8.06	STARS	A Randomised comparison of anastrozole commenced before and continuing during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy.	Peter Graham	A	Open (Follow up)
7.01	DCIS	A randomised phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in-situ (DCIS) of the breast	Boon Chua	A	Open (Follow up)
16.03	CORE	A randomised trial of Conventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases	(Farshad Foroudi & David Pryor)	B	Open (Follow up)
15.02	ROAM	Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (The ROAM trial)	(Nedi Hagihigh)	B	Open (Follow up)
14.02	RAIDER	A randomised phase II trial of adaptive image guided standard or dose escalated radiotherapy in the treatment of transitional cell carcinoma of the bladder	(Farshad Foroudi)	B	Open (Follow up)
6.01	Low Grade Glioma	Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study	(Claire Phillips)	B	Open (Follow up)
20.03	AVATAR	Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer	Steven David	C	Open (Follow up)
14.01	ENZARAD	Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer	Scott Williams	C	Open (Follow up)
8.08	TOPGEAR	A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemo therapy for resectable gastric cancer.	Trevor Leong	C	Open (Follow up)
8.04	PORTEC-3	Randomised phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial carcinoma	(Pearly Khaw)	C	Open (Follow up)

OVERALL ACCRUAL (31 December 2023)

OVERALL TROG ACCRUAL	
2018	14602
2019	14715
2020	14821
2021	14946
2022	15119
2023	15350




RECRUITING TRIALS UPDATE (01 March 2024)



TRIAL PORTFOLIO (01 March 2024)

TRIAL STATUS	CATEGORY				TOTAL
	A	B	C	D	
New Proposal	1	0	0	0	1
Development	6	3	5	0	14
Start Up	0	0	1	0	1
Open	12	4	11	0	27
Closed	19	6	5	0	30
Completed	39	8	2	0	49
Data Requests	0	0	0	25	25
TOTAL	77	21	24	25	147


TRIAL PORTFOLIO (01 Mar 2024)




TRIAL PORTFOLIO (01 March 2024)

SUBSPECIALTY	NEW PROPOSAL	DEVELOPMENT	START UP	OPEN	CLOSED	COMPLETED	DATA REQUESTS	TOTAL
	Breast	0	0	0	5	7	1	0
CNS	1	2	0	3	0	4	0	10
GI	0	1	1	4	2	12	2	22
GU	0	4	0	6	5	7	7	29
Gynae	0	0	0	2	0	1	0	3
H&N	0	0	0	0	5	5	8	18
Lung	0	3	0	2	3	2	6	16
Lymphoma	0	0	0	0	4	3	0	7
Multiple	0	3	0	3	1	2	2	11
Skin	0	1	0	2	2	4	0	9
Symptom Management	0	0	0	0	1	8	0	9
	1	14	1	27	30	49	25	147

TRIAL PORTFOLIO



TRIAL PORTFOLIO; Subspeciality vs Status (01 March 2024)




TSC Membership


Elected Positions	Name
TSC Chair	Sashendra Senth
Radiation Oncologists	Peter Gorayski Yoo Young (Dominique) Lee Lachlan MacDowell (<i>HNCIG Representative</i>)
Statistician	Chris Brown
Radiation Therapist	Shivani Kumar (<i>Publications Chair</i>)
Medical Oncologist	James Lynam
Physics	Paul Keall (<i>until March 2024</i>)
Consumer Representative	John Stubbs
Interventional Oncology	Jonathan Tibballs

Ex officio Positions	Name
National Technical Service: Health Economics	Richard De Abreu Lourenço
National Technical Service: Quality of Life	Brendan Mulhern
TROG Management	Renee Swanson (<i>Research</i>) Alisha Moore (<i>RTQA</i>)
Secretariat	Rebecca Montgomery
GCCTI Representative	Joseph Sia

TSC Schema



TROG Working Parties



The primary role of the working parties is to advise the TROG Scientific Committee on;

- Current trials and projects in the subspecialty research portfolio (*from development to completion*)
- Any gaps in research activities and research priorities to be adopted by TROG
- New research concepts including the scientific merit of the proposal
- Involve a multidisciplinary team including consumers to add value to the trial design

TROG Working Parties

	BREAST	CENTRAL NERVOUS SYSTEM	GENITOURINARY	HEAD NECK SKIN	LUNG
CHAIR	Farshad Foroudi	Mark Pinkham	Wee Loon Ong	Charles Lin	Fiona Hegi-Johnson
DEPUTY CHAIR	Tomas Kron	Kylie Jung	Niluja Thiru	Lachlan McDowell	Yu Yang Soon
MEMBERS	<p>Anelyn Chui Boon Chua Chia May Wong Janice Yeh Jenna Dean Joerg Lehmann Kylie Jung Melissa James Robyn Cheuk Steven David Vikash Patel</p>	<p>Alexandre Santos Andrew Pullar Andrew Scott Claire Phillips Dione Liefman Eng-Siew Koh Frank Saran Hien Le John Ryan John Shakeshaft Joseph Sia Peter Gorayski Peter Kerstens Senthilkumar Gandhidasan Shona Edwards Sagun Parakh Wee Loon Ong</p>	<p>Alison Brown Charles Lin David Pryor Eric Wegener Farshad Foroudi Margot Lehman Michael Huo Muhammad Ali Paul Keall Robyn Cheuk Shreya Armstrong Shankar Siva Stephen Chin Suki Gill</p>	<p>Albert Tiong Andrew Macann Annette Lim Anna Lawless Brett Hughes Bruce Ashford Chris Wratten Clare Bajraszewski Daniel Xing Danny Rischin Dione Liefman Eric Wegener Howard Liu James Sandison Joe Chang June Corry Lessandra Yan Shan Chee Liz Kenny Marcus Hu Margaret Chua Puma Sundaresan Rahul Ladwa Rathan Subramaniam Sandro Porceddu Sweet Ping Ng Thanuja Thachil Tsien Fua</p>	<p>Brett Hughes Chris Brown Eric Hau Jane Ludbrook Margot Lehman Mark Pinkham Michael Macmanus Sagun Parakh Shalini Vinod Susan Ann McCullough Tao Mai Tomas Kron Wen Xu</p>

TROG WORKING PARTIES

TROG WELCOMES MEMBERS FROM ALL AREAS OF RESEARCH TO JOIN OUR MULTIDISCIPLINARY WORKING PARTIES SPECIALISING IN:

- **BREAST**
- **CENTRAL NERVOUS SYSTEM**
- **GENITOURINARY**
- **HEAD, NECK & SKIN**
- **LUNG CANCER**

REGISTER YOUR INTEREST



TROG
CANCER
RESEARCH

Secondary Data Analysis Committee (SDAC)

Oversees the development of guidelines and procedures for secondary analysis of TROG data

Position	Name
Medical Physicist	Martin Ebert (Chair)
	Vanessa Panettieri
	Lois Holloway
	Michael Bailey
Radiation Oncologist	Dionee Liefman
	Sweet Ping Ng
Radiation Therapist	Kenton Thompson
	Stuart Greenham
Statistician	Val GebSKI
Health Economist	Richard De Abreu Lourenco
Trial Coordinator	Tracy Pearl-Larson
TROG RTQA	Alisha Moore
TROG Research Services Manager	Renee Swanson

New Techniques and Technology Committee (NTTC)

Ensures that up-to-date guidelines and procedures are available for the implementation of new technologies in TROG clinical trials

Position	Name	
Medical Physicist	Nick Hardcastle (Chair) Martin Ebert Rhonda Brown Michael Bailey Annette Haworth Lois Holloway Tomas Kron	Joerg Lehmann John Shakeshaft Peter Greer Andrew Cousins Michael Jameson Dean Wilkinson (Deputy Chair)
Radiation Oncologist	Farshad Foroudi Ben Hindson	
Radiation Therapist	Rob McDowall Kenton Thompson David Willis	
TROG RTQA	Alisha Moore Olivia Cook	

Independent Data and Safety Monitoring Committee (IDSMC)

Monitors progress of all TROG phase III and late phase II clinical trials in relation to quality processes and procedure and ensures the safety of patients and that wherever possible, each trial meets its primary objectives.

Position	Name
Radiation Oncologist	Bryan Burmeister (Chair) Lara Best Paul Nguyen
Statistician	Peta Forder
Surgical Oncologist	Nicholas Oddone-Baridon
Medical Oncologist	Michael Michael
Secretariat	Wendy Paterson

TROG Publications Committee (TPC)

Provides peer review in the form of independent scientific review of material and timelines, helping to maintain high standards and encouraging accurate, thorough and credible research reporting

Position	Name
Radiation Therapist	Shivani Kumar (Chair)
Radiation Oncologist	Sashendra Senth
Statistician	Chris Brown
Secretariat	Ryan Davey

2023 PUBLICATIONS

CAT	TROG No.	CITATION
A	21.12 ASPIRE	Khong J, Tee H, Gorayski P, Le H, Penniment M, Jessop S, Hansford J, Penfold M, Green J, Skelton K, Saran F. Proton beam therapy in paediatric cancer: Anticipating the opening of the Australian Bragg Centre for Proton Therapy and Research. <i>J Med Imaging Radiat Oncol</i> . 2023 Dec 25. doi: 10.1111/1754-9485.13614. Epub ahead of print. PMID: 38146017.
A	17.03 LARK	Sengupta C, Nguyen DT, Moodie T, Mason D, Luo J, Causer T, Liu SF, Brown E, Inskip L, Hazem M, Chao M, Wang T, Lee YY, van Gysen K, Sullivan E, Cosgriff E, Ramachandran P, Poulsen P, Booth J, O'Brien R, Greer P, Keall P. The first clinical implementation of real-time 6 degree-of-freedom image-guided radiotherapy for liver SABR patients. <i>Radiother Oncol</i> . 2023 Nov 24;190:110031. doi: 10.1016/j.radonc.2023.110031. Epub ahead of print. PMID: 38008417.
A	13.01 SAFRON II	Bucknell NW, Hardcastle N, Bressel M, Moore A, Montgomery R, Murnane A, Mai GT, Ball D, Kron T, Siva S; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Impact on Pulmonary Function in a Randomized Trial of Single-Fraction and Multifraction Stereotactic Body Radiation Therapy for Pulmonary Oligometastatic Disease: An Analysis of TROG 13.01 (SAFRON II). <i>Int J Radiat Oncol Biol Phys</i> . 2023 Oct 21:S0360-3016(23)08005-7. doi: 10.1016/j.ijrobp.2023.09.052. Epub ahead of print. PMID: 37871885.
A	14.02 RAIDER	Huddart R, Hafeez S, Omar A, Alonzi R, Birtle A, Cheung KC, Choudhury A, Foroudi F, Gribble H, Henry A, Hilman S, Hindson B, Lewis R, Muthukumar D, McLaren DB, McNair H, Nikapota A, Olorunfemi A, Parikh O, Philipps L, Rimmer Y, Syndikus I, Tolentino A, Varughese M, Vassallo-Bonner C, Webster A, Griffin C, Hall E. Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. <i>Clin Oncol (R Coll Radiol)</i> . 2023 Sep;35(9):586-597. doi: 10.1016/j.clon.2023.05.002. Epub 2023 May 9. PMID: 37225552.
A	09.02 CHISEL	Bucknell NW, Kron T, Herschtal A, Hardcastle N, Irving L, MacManus M, Hanna GG, Moore A, Murnane A, Siva S, Ball D; CHISEL coauthors. Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial. <i>Int J Radiat Oncol Biol Phys</i> . 2023 Oct 1;117(2):378-386. doi: 10.1016/j.ijrobp.2023.04.009. Epub 2023 Apr 21. PMID: 37087060.

2023 PUBLICATIONS

CAT	TROG No.	CITATION
A	18.06 FIG	(EDITORIAL) Barry N, Francis RJ, Ebert MA, Koh ES, Rowshanfarzad P, Hassan GM, Kendrick J, Gan HK, Lee ST, Lau E, Moffat BA, Fitt G, Moore A, Thomas P, Pattison DA, Akhurst T, Alipour R, Thomas EL, Hsiao E, Schembri GP, Lin P, Ly T, Yap J, Kirkwood I, Vallat W, Khan S, Krishna D, Ngai S, Yu C, Beuzeville S, Yeow TC, Bailey D, Cook O, Whitehead A, Dykyj R, Rossi A, Grose A, Scott AM. Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06. Eur J Nucl Med Mol Imaging. 2023 Aug 11. doi: 10.1007/s00259-023-06371-5. Epub ahead of print. PMID: 37563351.
		Koh ES, Gan HK, Senko C, Francis RJ, Ebert M, Lee ST, Lau E, Khasraw M, Nowak AK, Bailey DL, Moffat BA, Fitt G, Hicks RJ, Coffey R, Verhaak R, Walsh KM, Barnes EH, De Abreu Lourenco R, Rosenthal M, Adda L, Foroudi F, Lasocki A, Moore A, Thomas PA, Roach P, Back M, Leonard R, Scott AM. [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. BMJ Open. 2023 Aug 4;13(8):e071327. doi: 10.1136/bmjopen-2022-071327. PMID: 37541751; PMCID: PMC10407346.
		Langen KJ, Galldiks N, Lohmann P, Mottaghy FM. Boosting the acceptance of 18F-FET PET for image-guided treatment planning with a multi-centric prospective trial. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):3817-3819. doi: 10.1007/s00259-023-06426-7. PMID: 37682302; PMCID: PMC10611633.
A	3.04 RADAR	Ong, W. L., Nikitas, J., Joseph, D. J., Steigler, A., Denham, J. W., Millar, J. L., . . . Kishan, A. U. (2023). Patient-Reported Urinary and Bowel Quality of Life Outcomes Following External Beam Radiotherapy with or without High-Dose-Rate Brachytherapy Boost: Post-Hoc Analyses of TROG 03.04 (RADAR).. Int J Radiat Oncol Biol Phys, 117(2S), S93-S94. doi:10.1016/j.ijrobp.2023.06.424
		Ong, W. L., Nikitas, J., Joseph, D., Steigler, A., Millar, J., Valle, L., . . . Kishan, A. U. (2023). Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR. International Journal of Radiation Oncology Biology Physics. doi:10.1016/j.ijrobp.2023.09.051
-	-	Nguyen H, Montgomery R, Sundaresan P. Characteristics of chief investigators and principal investigators in Australian and New Zealand radiation oncology clinical trials. J Med Imaging Radiat Oncol. 2023 Jul 16. doi: 10.1111/1754-9485.13564. Epub ahead of print. PMID: 37454368.

2024 Publications

CAT	TROG No.	CITATION
A	15.03 FASTRACK II	Siva S, Bressel M, Sidhom M, Sridaran S, Vanneste B, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Rama A, Hardcastle N, Hofman M, DeAbreu Lourenco R, Shaw M, Mancuso P, Moon D, Wog L, Lawrentschuk N, Wood S, Brook N, Kron T, Martin J, Pryor D (2024) Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. <i>The Lancet</i> . 2024 Mar; 25(3):308-316. DOI: https://doi.org/10.1016/S1470-2045(24)00020-2
A	16.02 Local HER-O	Phillips C, Pinkham MB, Moore A, Sia J, Jeffree RL, Khasraw M, Kam A, Bressel M, Haworth A. Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02). <i>Breast</i> . 2024 Feb 5;74:103675. doi: 10.1016/j.breast.2024.103675. Epub ahead of print. PMID: 38340685.

THANK YOU!

- TSC Members
- Subcommittees
 - Subspecialty Working Parties
 - New Techniques and Technologies Committee
 - Independent Data and Safety Monitoring Committee (IDSMC)
 - TROG Publications Committee
 - Secondary Analysis Committee
- TCOO Staff: Jessica Piotrowski, Rebecca Montgomery, Renee Swanson, Alisha Moore, Susan Goode and the rest of the TROG team.
- TROG is supported by over 300 clinical trial committee volunteers, providing 800+ hours of time and valued service to TROG each year.